-
Inland Northwest Research Screens First Patient Worldwide for Study of Investigational Parkinson’s Disease Drug Posted on by Taylor Disselhorst in Press Releases
-
Statement to the FDA on Support for Aducanumab for Treatment of Early Stage AD Posted on by Taylor Disselhorst in Press Releases
-
USF Awarded Five-Year, $44.4 Million NIH Grant to Test Whether Computerized Brain Training Reduces Dementia Risk Posted on by Taylor Disselhorst in In the News
-
KU Alzheimer’s Disease Center Receives Over $1 Million for Research Posted on by Taylor Disselhorst in In the News
-
KU Alzheimer’s Disease Center Using $4.3 Million NIH Grant to Power its Research and Dementia Care Efforts Posted on by Taylor Disselhorst in In the News&Network
-
Donanemab Confirms: Clearing Plaques Slows Decline—By a Bit Posted on by Taylor Disselhorst in In the News
-
Can Changes in Driving Habits Predict Cognitive Decline in Older Adults? Posted on by Taylor Disselhorst in In the News
-
Lilly’s TRAILBLAZER-ALZ 2 Trial is Partnering with the Global Alzheimer’s Platform Foundation® to Shatter the Slow Completion Timeframes of Alzheimer’s Clinical Trials Posted on by Taylor Disselhorst in Press Releases
-
U.S. Trials for Alzheimer’s “Seaweed Drug” Oligomannate Recruiting Participants Posted on by Taylor Disselhorst in Featured&In the News
-
This Alzheimer’s Drug Made From Seaweed got Approved in China. Now it’s Being Tested in N.J. Posted on by Taylor Disselhorst in In the News
